Pipeline Moves: Advancement prospects plunge for oesophageal adenocarcinoma therapy
The Clinical Trials Arena team also review assets in metabolic disorders, gastrointestinal and oncology indications.
07 August 2023
07 August 2023
The Clinical Trials Arena team also review assets in metabolic disorders, gastrointestinal and oncology indications.
Eli Lilly’s LIBRETTO-431 study demonstrated a statistically significant improvement in progression-free survival for NSCLC patients.
Bevacizumab improved surgery success and reduced intraocular pressure in glaucoma patients who underwent trabeculectomy.
On day 22, chikungunya neutralising antibodies were found in 98% of vaccinees.
The treatment is indicated to improve glycemic control in type 2 diabetes adults, including those with chronic kidney disease.
Following the publication of Phase II trial results and marketing approval in China for the bispecific antibody, Akeso has started five pivotal Phase III trials.
Reduction in central alpha and beta power as well as increase in central delta power were observed in the active group.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.